Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 32-38

  Rengelshausen, Jens ^a   Göggelmann, Christoph ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Ludwig, Jochen ^a   Weiss, Johanna ^a   Mikus, Gerd ^a   Walter Sack, Ingeborg ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bioavailability; Clarithromycin; Digoxin; Drug interactions; Human; P glycoprotein

Indexed keywords

CLARITHROMYCIN; DIGOXIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGOXIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CLARITHROMYCIN; CREATININE; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GENES, MDR; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 0038336620     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01824.x     Document Type: Article

References (30)

1. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann. Pharmacother 1997; 31: 1077-1079.
2. Xu H, Rashkow A. Clarithromycin-induced digoxin toxicity: a case report and a review of the literature. Conn. Med 2001; 65: 527-529.
3. Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981; 305: 789-794.
4. Wakasugi H, Yano I, Ito T et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123-128.
5. 1). J Pharmacol Exp Ther 1992; 263: 840-845.
6. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
7. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266: 1620-1625.
8. Buclin T, Pechère-Bertschi A, Séchaud R et al. Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol 1997; 37: 679-692.
9. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385-398.
10. Schneider CA, Diedrichs H, Riedel KD, Zimmermann T, Hopp HW. In vivo uptake of azithromycin in human coronary plaques. Am J Cardiol 2000; 86: 789-791.
11. McLachlan AJ, Gross AS, Beal JL, Minns I, Tett SE. Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Ther Drug Monit 2001; 23: 39-46.
12. Soper CP, Bending MR, Barton JL. An automated enzymatic inulin assay, capable of full sinistrin hydrolysis. Eur J Clin Chem Clin Biochem 1995; 33: 497-501.
13. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
14. Nauck M, Stein U, von Karger S, März W, Wieland H. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridisation probes. Clin Chem 2000; 46: 1996-1997.
15. Steiness E, Waldorff S, Hansen PB. Renal digoxin clearance: dependence on plasma digoxin and diuresis. Eur J Clin Pharmacol 1982; 23: 151-154.
16. Bonate PL, Reith K, Weir S. Drug interactions at the renal level. Implications for drug development. Clin Pharmacokinet 1998; 34: 375-404.
17. Ochs HR, Greenblatt DJ, Bodem G, Harmatz JS. Dose-independent pharmacokinetics of digoxin in humans. Am Heart J 1978; 96: 507-511.
18. Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF. A prospective study of the clarithromycin-digoxin interaction in elderly patients. J Antimicrob Chemother 2002; 50: 601-606.
19. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-613.
20. Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988; 15: 165-179.
21. Hinderling PH, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991; 13: 381-401.
22. Lacarelle B, Rahmani R, de Sousa G, Durand A, Placidi M, Cano JP. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991; 5: 567-582.
23. Dobkin JF, Saha JR, Butler VP, Neu HC. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220: 325-327.
24. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984; 86: 174-193.
25. Kennedy M, Chinwah P, Wade DN. A pharmacological method of measuring mouth caecal transit time in man. Br J Clin Pharmacol 1979; 8: 372-373.
26. 3H]digoxin in man. Clin Sci 1972; 43: 507-518.
27. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287.
28. Cavet ME, West M, Simmons NL. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1996; 118: 1389-1396.
29. Greiner B, Eichelbaum M, Fritz P et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin. J Clin Invest 1999; 104: 147-153.
30. Kurata Y, Ieiri I, Kimura M et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209-219.